Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Summary of Significant Accounting Policies

Summary of the items included within net loss regularly provided to the CODM

	Year ended December 31,
	2025		2024		2023
Revenue	$	80,275	$	69,300	$	58,453
Cost of revenue (excluding amortization of intangible assets)		25,554		22,432		17,961
Amortization of intangible assets		380		380		380
Gross profit		54,341		46,488		40,112
Sales and marketing:
Sales and sales management		43,365		44,132		35,469
International		5,711		5,072		3,916
Other sales and marketing (a)		14,106		15,444		20,296
Total sales and marketing		63,182		64,648		59,681
General and Administrative:
Finance and Legal		7,461		7,503		7,715
Other general and administrative (b)		8,233		7,219		7,172
Total general and administrative		15,694		14,722		14,887
Research and Development:
Clinical		3,568		4,068		3,891
Regulatory and quality		2,158		1,452		2,189
Other research and development (c)		3,494		3,293		3,539
Total research and development		9,220		8,813		9,619
Gain on sale of product line		—		7,580		—
Other segment items (d)		(5,076)		(3,726)		(2,589)
Net loss	$	(38,831)	$	(37,841)	$	(46,664)
(a) Other sales and marketing includes strategy, analytics and allocated facility expenses.
(b) Other general and administrative includes executive, human resources, information technology and allocated facility expenses.
(c) Other research and development includes engineering and allocated facility expenses.
(d) Other segment items include other operating income and other expenses as disclosed in the consolidated statements of operations and comprehensive loss; interest expense, loss on extinguishment of debt, other income and income tax expense.

Schedule of reconciliation of all captions of cash, cash equivalents and restricted cash

	December 31,
	2025		2024
Cash and cash equivalents	$	50,845	$	52,670
Restricted cash		250		265
Total cash and cash equivalents and restricted cash shown in statements of cash flows	$	51,095	$	52,935

Schedule of Inventory

Inventory consists of purchased materials, primarily finished goods, and is identified and tracked by lot and stated at the lower of cost or net realizable value, with cost being determined on a first-in, first-out basis. Inventories consisted of the following (in thousands):

	December 31,
	2025		2024
Finished goods	$	10,898	$	12,645
Raw materials		118		136
Total inventory	$	11,016	$	12,781

Disaggregation of Revenue

The following table presents revenue disaggregated (in thousands):

	Year ended December 31,
	2025		2024		2023
OviTex	$	51,224	$	45,925	$	39,416
OviTex PRS		27,306		22,745		18,736
Other		1,745		630		301
Total revenue	$	80,275	$	69,300	$	58,453

Schedule of fair value of assets and liabilities measured on recurring basis

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis (in thousands):

	Fair value measurement at reporting date using
	Quoted prices in
	active markets		Significant other		Significant
	for identical		observable		unobservable
	assets		inputs		inputs
	(Level 1)		(Level 2)		(Level 3)
December 31, 2025:
Cash equivalents – money market fund	$	47,068	$	—	$	—
December 31, 2024:
Cash equivalents – money market fund	$	48,131	$	—	$	—

Schedule of allowance for credit losses

The following table presents a rollforward of the allowance of credit losses (in thousands):

		Balance at Beginning of Period	Bad Debt Expense Recognized	Write-offs of Uncollectible Balances		Balance at End of Period
Year ended December 31, 2023	$	(143)	(306)	33	$	(416)
Year ended December 31, 2024	$	(416)	(65)	206	$	(275)
Year ended December 31, 2025	$	(275)	(97)	85	$	(287)

Schedule of dilutive securities excluded

	Year ended December 31,
	2025	2024	2023
Stock options	2,672,859	2,119,183	2,162,453
Unvested restricted stock units	1,321,162	948,788	907,203
Common stock warrants	88,556	88,556	88,556
Common stock warrants issued with credit facility	2,000,000	—	—
Total	6,082,577	3,156,527	3,158,212